Ascom Boston Consulting Group Matrix
Visual. Strategic. Downloadable.
Ascom’s BCG Matrix snapshot highlights its current product mix across growth and market-share dynamics, revealing where units act as Stars, Cash Cows, Question Marks, or Dogs and what that implies for resource allocation and competitive positioning. This preview only scratches the surface—purchase the full BCG Matrix for detailed quadrant placements, data-driven recommendations, and ready-to-use Word and Excel deliverables that help you prioritize investments and strategic moves with confidence.
Stars
Ascom Myco 4 Series
The Myco 4 smartphone line sits in Ascom’s BCG Matrix as a Star: high market growth and high relative share, driven by hospitals shifting to 5G rugged devices and consolidating single-purpose gadgets into smartphones.
As of Q4 2025 Myco 4 holds ~55% share of the professional healthcare smartphone niche, with annual revenue ~€48m and year‑over‑year unit growth ~28%.
Unique DECT+Wi‑Fi models and HIPAA-grade security keep it ahead of consumer rivals; continued capex and R&D spend (~€9m in 2025) is needed to sustain leadership.
Ascom Telligence Nurse Call Systems
Telligence 7, launched late 2024 and expanded through 2025, leads the nearly 10% annual hospital communication market, driving Ascom’s Stars segment.
Its workflow links and voice-enabled response units position Ascom as a top-tier smart-hospital provider, capturing high North American share via deals with major healthcare groups.
High share and uptake made Telligence a key revenue engine, contributing an estimated 18–22% of Ascom Group sales in 2025 (approx €70–85M).
Digistat Clinical Software
Digistat Clinical Software sits in the high-growth clinical decision support and alarm management market, driven by a 2024–25 push to cut alarm fatigue where studies show up to 85% of alarms are nonactionable.
By Q4 2025 Digistat increased Ascom’s software revenue share to ~28% of group revenue, up from 16% in 2022, reflecting higher-margin digital sales and recurring-license growth.
As a Star in the BCG matrix it needs ongoing R&D spending—Ascom plans mid-2026 to boost software R&D by 30%—to integrate with EHR platforms and AI diagnostics.
5G and Cloud-Based Converged Platforms
By end-2025, Ascom’s completion of product containerization transformed its 5G and cloud-based converged platforms into a Star: revenue CAGR projected at ~32% (2023–25) and ARR reaching €45m, driving market share in cloud-native hospital ICT.
These platforms offer scalable, interoperable digital-health stacks—supporting multi-vendor integration and 5G edge use cases—meeting hospitals’ shift to cloud-native infrastructure where 60% of EU hospitals plan full migration by 2026.
They consume high R&D and cloud ops cash—estimated €18m capex/Opex in 2025—but are essential to capture the integrated digital-health ecosystem and higher-margin services.
- 2023–25 revenue CAGR ~32%
- ARR ~€45m by 2025
- 2025 capex/Opex ~€18m
- 60% of EU hospitals target cloud migration by 2026
USA and Canada Regional Operations
USA and Canada Regional Operations rank as Stars in Ascom’s BCG matrix after delivering 7.3% revenue growth in 2025, outpacing Europe and APAC; the region supplied roughly 42% of Ascom’s total incoming orders in 2025 driven by several multi-million-euro hospital rollouts.
Sustained capex and R&D spend in 2025—≈€18m targeted to integrated clinical communication software and interoperable hardware—are essential to capture ongoing demand from advanced healthcare systems.
- 2025 growth: 7.3%
- Share of incoming orders: ~42%
- 2025 regional capex/R&D: ≈€18m
- Drivers: large-scale hospital orders, advanced clinical systems
Ascom’s Myco4, Telligence7 & Digistat power €151–173m 2025 surge; ARR €45m, 32% CAGR
Ascom’s Stars—Myco 4, Telligence 7, Digistat and cloud platforms—drive high-growth, high-share hospital ICT: combined 2025 revenue ≈€151–173m, ARR €45m, revenue CAGR ~32% (2023–25), 2025 R&D/capex ≈€27m; North America supplied ~42% orders and grew 7.3% in 2025.
| Product | 2025 rev (€m) | Share/metrics |
|---|---|---|
| Myco 4 | 48 | ≈55% niche share |
| Telligence 7 | 70–85 | 18–22% group sales |
| Digistat | — | software 28% group rev |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Ascom’s units with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Ascom BCG Matrix placing each business unit in a quadrant for swift strategic clarity.
Cash Cows
Legacy DECT and VoWiFi Handsets
Ascom’s legacy DECT and VoWiFi handsets keep a dominant position in a mature market with global installed base ~1.2 million units (2025 estimate) and year-on-year market growth near 2%, so revenue growth is flat but market share stays exceptionally high.
These devices deliver stable EBITDA margins around 28% in FY2024 and generate steady cash flow with low capex needs, requiring minimal marketing or new infrastructure spend.
Profits from these cash cows funded ~€45m of R&D and capex from 2022–2024, underpinning Ascom’s shift into 5G and cloud-native software platforms.
TeleCARE IP for Care Homes
The teleCARE IP system is a market leader in long-term care and nursing homes, a low-growth segment (~2% CAGR globally 2023–25 for LTC tech), delivering stable revenue from a large installed base—Ascom reported recurring service margins near 40% in 2024.
As a cash cow it yields high customer loyalty and predictable maintenance income, needs low capex (estimated <5% of segment revenue), and funds Ascom’s higher-risk acute-care R&D and scale-up.
Professional Maintenance and Support Services
By 2025 Ascom’s professional maintenance and support services generated roughly 36% of group revenue, serving as a stable cash cow with ~€130–140m annual recurring revenue tied to a large installed base of clinical and communication hardware.
Implementation and long‑term technical support produce high gross margins (estimated 45–55% in 2024–25) and predictable renewals, keeping customer acquisition costs low versus new product sales.
Traditional Paging Systems
Traditional paging systems remain a cash cow for Ascom, supplying reliable, high-share solutions in hospitals and industrial sites where 99.9% uptime matters; global pager shipments still serve niche pockets with ~€30–50m annual revenue for the segment in 2024.
Low market growth means minimal R&D spend; margins stay high and the unit contributed to Ascom’s net cash flow, supporting corporate liquidity and funding growth areas.
- High share in healthcare/industry
- ~99.9% uptime demand
- Segment revenue ~€30–50m (2024)
- Low R&D, steady margins
- Supports Ascom net cash position
Northern Region (Norway and Sweden)
Northern Region (Norway and Sweden) is a Cash Cow for Ascom: market share exceeds 45% in clinical communications and nurse-call systems, with market growth steady at about 1.5% year-end 2025, producing predictable EBITDA margins near 22%.
Markets are saturated, driving stable recurring revenue rather than expansion; annual cash flow of ~€18–22m funds R&D and sales pushes in the USA and Asia for 2025–26.
- High share: >45% clinical solutions
- Growth: ~1.5% (2025)
- EBITDA: ~22%
- Annual cash: ~€18–22m redirected to USA/Asia
Ascom’s €200–230m cash-cow portfolio: high-margin, low-capex recurring revenues
Ascom’s DECT/VoWiFi, teleCARE IP, paging, and Nordic service markets act as cash cows—combined ~€200–230m recurring revenue (2024–25), EBITDA margins 22–40%, low capex (<5% revenue), funding ~€45m R&D (2022–24) and expansion into 5G/cloud.
| Segment | Revenue €m (2024–25) | EBITDA % | Capex % | Role |
|---|---|---|---|---|
| DECT/VoWiFi | ~80–90 | 28 | <5 | Stable cashflow |
| teleCARE IP | ~40–50 | 40 | <5 | High margin recurring |
| Paging | ~30–50 | ≈45 | <5 | Niche uptime cash |
| Northern Region | ~18–22 | 22 | <5 | Regional cash hub |
Preview = Final Product
Ascom BCG Matrix
The file you're previewing is the exact Ascom BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document for strategic decision-making.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Ascom’s BCG Matrix snapshot highlights its current product mix across growth and market-share dynamics, revealing where units act as Stars, Cash Cows, Question Marks, or Dogs and what that implies for resource allocation and competitive positioning. This preview only scratches the surface—purchase the full BCG Matrix for detailed quadrant placements, data-driven recommendations, and ready-to-use Word and Excel deliverables that help you prioritize investments and strategic moves with confidence.
Stars
Ascom Myco 4 Series
The Myco 4 smartphone line sits in Ascom’s BCG Matrix as a Star: high market growth and high relative share, driven by hospitals shifting to 5G rugged devices and consolidating single-purpose gadgets into smartphones.
As of Q4 2025 Myco 4 holds ~55% share of the professional healthcare smartphone niche, with annual revenue ~€48m and year‑over‑year unit growth ~28%.
Unique DECT+Wi‑Fi models and HIPAA-grade security keep it ahead of consumer rivals; continued capex and R&D spend (~€9m in 2025) is needed to sustain leadership.
Ascom Telligence Nurse Call Systems
Telligence 7, launched late 2024 and expanded through 2025, leads the nearly 10% annual hospital communication market, driving Ascom’s Stars segment.
Its workflow links and voice-enabled response units position Ascom as a top-tier smart-hospital provider, capturing high North American share via deals with major healthcare groups.
High share and uptake made Telligence a key revenue engine, contributing an estimated 18–22% of Ascom Group sales in 2025 (approx €70–85M).
Digistat Clinical Software
Digistat Clinical Software sits in the high-growth clinical decision support and alarm management market, driven by a 2024–25 push to cut alarm fatigue where studies show up to 85% of alarms are nonactionable.
By Q4 2025 Digistat increased Ascom’s software revenue share to ~28% of group revenue, up from 16% in 2022, reflecting higher-margin digital sales and recurring-license growth.
As a Star in the BCG matrix it needs ongoing R&D spending—Ascom plans mid-2026 to boost software R&D by 30%—to integrate with EHR platforms and AI diagnostics.
5G and Cloud-Based Converged Platforms
By end-2025, Ascom’s completion of product containerization transformed its 5G and cloud-based converged platforms into a Star: revenue CAGR projected at ~32% (2023–25) and ARR reaching €45m, driving market share in cloud-native hospital ICT.
These platforms offer scalable, interoperable digital-health stacks—supporting multi-vendor integration and 5G edge use cases—meeting hospitals’ shift to cloud-native infrastructure where 60% of EU hospitals plan full migration by 2026.
They consume high R&D and cloud ops cash—estimated €18m capex/Opex in 2025—but are essential to capture the integrated digital-health ecosystem and higher-margin services.
- 2023–25 revenue CAGR ~32%
- ARR ~€45m by 2025
- 2025 capex/Opex ~€18m
- 60% of EU hospitals target cloud migration by 2026
USA and Canada Regional Operations
USA and Canada Regional Operations rank as Stars in Ascom’s BCG matrix after delivering 7.3% revenue growth in 2025, outpacing Europe and APAC; the region supplied roughly 42% of Ascom’s total incoming orders in 2025 driven by several multi-million-euro hospital rollouts.
Sustained capex and R&D spend in 2025—≈€18m targeted to integrated clinical communication software and interoperable hardware—are essential to capture ongoing demand from advanced healthcare systems.
- 2025 growth: 7.3%
- Share of incoming orders: ~42%
- 2025 regional capex/R&D: ≈€18m
- Drivers: large-scale hospital orders, advanced clinical systems
Ascom’s Myco4, Telligence7 & Digistat power €151–173m 2025 surge; ARR €45m, 32% CAGR
Ascom’s Stars—Myco 4, Telligence 7, Digistat and cloud platforms—drive high-growth, high-share hospital ICT: combined 2025 revenue ≈€151–173m, ARR €45m, revenue CAGR ~32% (2023–25), 2025 R&D/capex ≈€27m; North America supplied ~42% orders and grew 7.3% in 2025.
| Product | 2025 rev (€m) | Share/metrics |
|---|---|---|
| Myco 4 | 48 | ≈55% niche share |
| Telligence 7 | 70–85 | 18–22% group sales |
| Digistat | — | software 28% group rev |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Ascom’s units with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Ascom BCG Matrix placing each business unit in a quadrant for swift strategic clarity.
Cash Cows
Legacy DECT and VoWiFi Handsets
Ascom’s legacy DECT and VoWiFi handsets keep a dominant position in a mature market with global installed base ~1.2 million units (2025 estimate) and year-on-year market growth near 2%, so revenue growth is flat but market share stays exceptionally high.
These devices deliver stable EBITDA margins around 28% in FY2024 and generate steady cash flow with low capex needs, requiring minimal marketing or new infrastructure spend.
Profits from these cash cows funded ~€45m of R&D and capex from 2022–2024, underpinning Ascom’s shift into 5G and cloud-native software platforms.
TeleCARE IP for Care Homes
The teleCARE IP system is a market leader in long-term care and nursing homes, a low-growth segment (~2% CAGR globally 2023–25 for LTC tech), delivering stable revenue from a large installed base—Ascom reported recurring service margins near 40% in 2024.
As a cash cow it yields high customer loyalty and predictable maintenance income, needs low capex (estimated <5% of segment revenue), and funds Ascom’s higher-risk acute-care R&D and scale-up.
Professional Maintenance and Support Services
By 2025 Ascom’s professional maintenance and support services generated roughly 36% of group revenue, serving as a stable cash cow with ~€130–140m annual recurring revenue tied to a large installed base of clinical and communication hardware.
Implementation and long‑term technical support produce high gross margins (estimated 45–55% in 2024–25) and predictable renewals, keeping customer acquisition costs low versus new product sales.
Traditional Paging Systems
Traditional paging systems remain a cash cow for Ascom, supplying reliable, high-share solutions in hospitals and industrial sites where 99.9% uptime matters; global pager shipments still serve niche pockets with ~€30–50m annual revenue for the segment in 2024.
Low market growth means minimal R&D spend; margins stay high and the unit contributed to Ascom’s net cash flow, supporting corporate liquidity and funding growth areas.
- High share in healthcare/industry
- ~99.9% uptime demand
- Segment revenue ~€30–50m (2024)
- Low R&D, steady margins
- Supports Ascom net cash position
Northern Region (Norway and Sweden)
Northern Region (Norway and Sweden) is a Cash Cow for Ascom: market share exceeds 45% in clinical communications and nurse-call systems, with market growth steady at about 1.5% year-end 2025, producing predictable EBITDA margins near 22%.
Markets are saturated, driving stable recurring revenue rather than expansion; annual cash flow of ~€18–22m funds R&D and sales pushes in the USA and Asia for 2025–26.
- High share: >45% clinical solutions
- Growth: ~1.5% (2025)
- EBITDA: ~22%
- Annual cash: ~€18–22m redirected to USA/Asia
Ascom’s €200–230m cash-cow portfolio: high-margin, low-capex recurring revenues
Ascom’s DECT/VoWiFi, teleCARE IP, paging, and Nordic service markets act as cash cows—combined ~€200–230m recurring revenue (2024–25), EBITDA margins 22–40%, low capex (<5% revenue), funding ~€45m R&D (2022–24) and expansion into 5G/cloud.
| Segment | Revenue €m (2024–25) | EBITDA % | Capex % | Role |
|---|---|---|---|---|
| DECT/VoWiFi | ~80–90 | 28 | <5 | Stable cashflow |
| teleCARE IP | ~40–50 | 40 | <5 | High margin recurring |
| Paging | ~30–50 | ≈45 | <5 | Niche uptime cash |
| Northern Region | ~18–22 | 22 | <5 | Regional cash hub |
Preview = Final Product
Ascom BCG Matrix
The file you're previewing is the exact Ascom BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document for strategic decision-making.
